NLS Global report

More than 40% of women in the US say their health has limited their career, and the share rises to 66% among women who cannot get the care they need, according to a new Gallup survey conducted in partnership with Pivotal.

With a new EUR 61 million facility in Vilnius, Northway Biotech becomes the first dedicated cell therapy and personalized medicine CDMO in the Baltics – a development that also expands manufacturing capacity within reach of the Nordic biotech sector.

The US FDA has approved RASONQUE (daraxonrasib), Revolution Medicines' once-daily pill, for adults with previously treated metastatic pancreatic adenocarcinoma — the first medicine to directly target RAS, the protein driving most pancreatic cancers.

AstraZeneca and partner Amgen have reported that Tezspire (tezepelumab) met both co-primary and all key secondary endpoints in the Phase III CROSSING trial in eosinophilic esophagitis (EoE), positioning the anti-TSLP antibody for a potential new indication beyond its existing approvals in severe asthma and chronic rhinosinusitis with nasal polyps.

Merck and Moderna have reported positive topline results from the Phase 3 INTerpath-001 trial of intismeran autogene in combination with Keytruda in patients with completely resected, high-risk melanoma.

The U.S. Food and Drug Administration (FDA) has approved mFLUSIVA (mRNA-1010), a new vaccine against seasonal influenza, for use in all adults 50 years and older.